An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Show Description +

David S. Boyer, MD, explains data from cohort 6 of the phase 2 AAVIATE study of RGX-314 (Regenxbio) for wet AMD.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Clinical Trials

•

REGENXBIO

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

Up Next

Name: An Update on Suprachoroidal RGX-314
Uploaded: 2023-08-08T15:35:28+00:00
Description: David S. Boyer, MD, explains data from cohort 6 of the phase 2 AAVIATE study of RGX-314 (Regenxbio) for wet AMD.

Treating GA With ANX007

Jeffrey S. Heier, MD

Introducing a TWO-ROP Algorithm

Nimesh A. Patel, MD

When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Methotrexate Shows Promise for Preventing PVR

Christina J. Flaxel, MD

Codes for Concurrent GA and Wet AMD

Jong G. Park, MD

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Defining Anti-VEGF Response in CI-DME

Sharon D. Solomon, MD

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Biosimilars in the Real World

Carl C. Awh, MD, FASRS

Back to All Videos

An Update on Suprachoroidal RGX-314

David S. Boyer, MD

David S. Boyer, MD, explains data from cohort 6 of the phase 2 AAVIATE study of RGX-314 (Regenxbio) for wet AMD.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Clinical Trials

•

REGENXBIO

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

An Update on Suprachoroidal RGX-314

Up Next

An Update on Suprachoroidal RGX-314

More From ASRS: 2023 Coverage